Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Payables (2023 - 2025)

CG Oncology's Payables history spans 3 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Payables fell 12.32% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, down 12.32%, while the annual FY2025 figure was $5.7 million, 12.32% down from the prior year.
  • Payables reached $5.7 million in Q4 2025 per CGON's latest filing, down from $9.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $11.3 million in Q3 2024 to a low of $3.2 million in Q4 2023.
  • Average Payables over 3 years is $6.9 million, with a median of $6.7 million recorded in 2025.
  • Peak YoY movement for Payables: surged 101.02% in 2024, then dropped 18.85% in 2025.
  • A 3-year view of Payables shows it stood at $3.2 million in 2023, then soared by 101.02% to $6.5 million in 2024, then decreased by 12.32% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Payables are $5.7 million (Q4 2025), $9.2 million (Q3 2025), and $7.1 million (Q2 2025).